Company profile: Chronos Therapeutics
1.1 - Company Overview
Company description
- Provider of age-related disease drug development, advancing SFX-01, a sulforaphane-based stable tablet for oncology and neurodevelopmental disorders; a highly selective orexin 1 receptor antagonist for addictive behaviors including binge eating disorder and alcohol use disorder; and an atypical DAT inhibitor for fatigue and narcolepsy, plus licensing and partnership collaborations.
Products and services
- Atypical Inhibitor of the Brain Dopamine Active Transporter (DAT): Atypical molecule modulating dopamine levels to target symptoms of fatigue and narcolepsy through DAT inhibition
- Highly Selective Orexin 1 Receptor Antagonist (Ox-1): Highly selective antagonist targeting addictive behaviors including binge eating disorder and alcohol use disorder via Orexin 1 receptor blockade
- SFX-01: Sulforaphane-based medicine formulated as a stable tablet targeting oncology and neurodevelopmental disorders, highlighting a robust, stable-tablet formulation for consistent compound integrity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chronos Therapeutics
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Pernix Therapeutics
HQ: United States
Website
- Description: Provider of branded and generic pharmaceutical products for the pediatric market, specializing in the sales, marketing, and development of products designed to improve children's health and well-being, including offerings in allergy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pernix Therapeutics company profile →
Prolong Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical products and development technologies, including PP-007 (Sanguinate), a PEGylated carboxyhemoglobin bovine product designed to deliver oxygen and carbon monoxide to hypoxic tissues to restore homeostasis and reduce inflammation, and PEGfinity, a PEGylation-based process that enhances the function and stability of therapeutic proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prolong Pharmaceuticals company profile →
Pieris Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology biotechnology programs, including 4-1BB bispecific programs developed with Pfizer, Servier, and Boston Pharmaceuticals, and potential future partnership royalties from sales of approved partnered immuno-oncology assets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pieris Pharmaceuticals company profile →
Annovation BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical products focused on anesthesia, sedation and sleep; incorporated in 2009 and based in Wayland, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovation BioPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chronos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chronos Therapeutics
2.2 - Growth funds investing in similar companies to Chronos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chronos Therapeutics
4.2 - Public trading comparable groups for Chronos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →